TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: In Vivo Efficacy Study of Patient Preoperative Preps

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects of any race~* Subjects in good health~* Minimum skin flora baseline requirements on abdomen and groin~Exclusion Criteria:~* Any tattoos, scars, breaks in the skin, or any form of dermatitis, or other skin disorders (including acne) on the applicable test area~* Topical antimicrobial exposure within 14 days prior to screening and treatment days~* Use of systemic or topical antibiotics, steroid medications, or any other products known to affect the normal microbial flora of the skin within 14 days prior to screening and treatment days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 3M CHG/IPA Prep C (Type: EXPERIMENTAL): Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
- 3M CHG/IPA Prep CH (Type: EXPERIMENTAL): Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
- ChloraPrep (Type: ACTIVE_COMPARATOR): Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
- Normal Saline (Type: PLACEBO_COMPARATOR): Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed squamous cell carcinoma of the head and neck~  * Stage III or IV disease~    * No evidence of distant metastases~ * No salivary gland or paranasal sinus squamous cell carcinoma~* No disease with close proximity to a major vessel~* Measurable disease~* No known CNS or brain metastases~  * Patients with intracranial extension without cerebral involvement may be eligible~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* Life expectancy \> 12 weeks~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 10 g/dL~* Bilirubin normal~* AST and ALT ≤ 2 times upper limit of normal~* PT normal~* Creatinine normal OR~* Creatinine clearance ≥ 60 mL/min~* Urine protein: creatinine ratio \< 1.0~* No bleeding diathesis or coagulopathy~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No history of allergic reaction attributed to compounds of similar chemical or biological composition to study drugs~* No pre-existing peripheral neuropathy ≥ grade 2~* No ongoing or active infection~* No serious non-healing wound, ulcer, or bone fracture~* No New York Heart Association class II-IV congestive heart failure~* No significant arrhythmias requiring medication~* No myocardial infarction within the past 6 months~* No stroke within the past 6 months~* No symptomatic coronary artery disease~* No second- or third-degree heart block or bundle branch block~* No unstable angina pectoris~* No hypertension (i.e., blood pressure ≥ 150/100 mm Hg)~* No other clinically significant heart disease~* No significant traumatic injury within the past 4 weeks~* No psychiatric illness or social situation that would preclude study compliance~* No HIV positivity~* No other malignancy within the past 5 years except squamous cell or basal cell skin cancer or carcinoma in situ of the cervix~* No other uncontrolled illness~* No poorly compliant patients~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy or radiotherapy~* No prior investigational anticancer agents~* More than 4 weeks since prior major surgery~* More than 1 week since prior minor surgery, fine-needle aspiration, or core needle biopsy~* No concurrent major surgery except planned neck dissection~* No concurrent routine colony-stimulating factor therapy~* No other concurrent investigational agents~* No other concurrent anticancer therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- bevacizumab with docetaxel and radiation therapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age at least 18 years~* hospitalization in an intensive care unit participating to the study~* medical diagnosis with SARS-CoV-2 pneumonia as defined by both:~  * extended interstitial pneumonia on CT scan or a chest X-ray, consistent with viral pneumonia, within 10 days prior to inclusion~ * Positive result of SARS-CoV-2 PCR test, or any emerging and validated diagnostic laboratory test for COVID-19, within 15 days prior to inclusion~* under mechanical ventilation administered through an endotracheal tube, for less than 5 days~* prior Clinical Frailty Scale \< 6.~* written consent of the patient, or - if impossible - of a relative acting as the legal representative, or - if impossible - of a physician from a non-participating department of the same hospital acting as an impartial witness .~Exclusion Criteria:~* Pregnancy~* Prior episode of transfusion-related side effect~* Medical decision to limit therapy~* Current participation in another trial testing a COVID-19 therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Convalescent Plasma (Type: EXPERIMENTAL): 2 units of plasma ( 400-500ml) from 2 different donnors duration of treatment =2 h
- Standard of care (Type: OTHER): Standard of care according the last gold standards

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria~* Male or female participants ≥ 12 to \< 17 years of age~* Chronic AD that has been documented for at least 2 years~* Eczema Area and Severity Index (EASI) score ≥ 16~* Investigator's Global Assessment (IGA) score ≥ 3~* AD involvement ≥ 10% of Body Surface Area (BSA)~* Documented recent history of inadequate response to topical medications~* Women of childbearing potential must agree to be strictly abstinent or to use an effective and approved method of contraception throughout the study and for 12 weeks after the last study drug injection.~Key Exclusion Criteria~* Body weight \< 30 kilogram (kg)~* Cutaneous infection within 1 week or any infection requiring treatment with oral or parenteral antibiotics, antivirals, antiparasitics, or antifungals within 1 week~* History of hypersensitivity (including anaphylaxis) to an immunoglobulin product (plasma-derived or recombinant, example., monoclonal antibody)~* Any medical or psychological condition, or any clinically relevant laboratory abnormalities that may have put the subject at significant risk according to the investigator's judgment

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Nemolizumab (Type: EXPERIMENTAL): Nemolizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rehabilitative Trial With Cerebello-Spinal tDCS in Neurodegenerative Ataxia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a cerebellar syndrome and quantifiable cerebellar atrophy~Exclusion Criteria:~* Severe head trauma in the past~* History of seizures~* History of ischemic stroke or hemorrhage~* Pacemaker~* Metal implants in the head/neck region~* Severe comorbidity~* Intake of illegal drugs~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Real tDCS (Type: EXPERIMENTAL): 10 days anodal cerebellar and cathodal spinal tDCS
- Sham tDCS (Type: SHAM_COMPARATOR): 10 days sham cerebellar and sham spinal tDCS

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An add-on Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-epileptic Drugs (AEDs)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~1. Male or female aged between 20 and 64 years old.~2. Patients diagnosed with partial seizure (including secondarily generalized seizure).~3. Patients who have at least 3 counts of partial seizures during the previous 4 weeks prior to observation start and no seizure-free for 21 days during 8 weeks before the treatment start based on medical records. Simple partial seizure without motor signs will not be counted.~4. Patients who have been treated for at least 12 weeks but confirmed to be uncontrolled with more than one standard AED for 2 years.~5. Patients treated with stable doses of up to three AEDs. Only one cytochrome~   P450 (CYP) 3A4 inducer shown below will be allowed for concomitant use:~  * Carbamazepine~  * Phenytoin~  * Phenobarbital~  * Primidone~6. Patients on stable dose of anti-depressants, anti-anxiety drugs, or mood stabilizers from before 8 weeks.~Exclusion criteria:~1. Patients with present or a history of Lennox-Gastaut syndrome.~2. Patients with present generalized seizures (e.g., absence, myoclonic).~3. Patients with a history of status epilepticus within 1 year.~4. Patients with seizure clusters where individual seizure cannot be counted within 8 weeks.~5. Patients with a history of psychogenic seizure.~6. Patients who underwent surgical operation for epilepsy within 2 years.~7. Patients using rescue benzodiazepines at least twice in a 4-week duration within 8 weeks (if 1 or 2 doses over 24-hour period considered one-time rescue).~8. Patients whose alanine aminotransferase (ALT) or aspartate aminotransferase (AST) at enrollment in observation period exceeds 1.5-fold the upper limit of normal (ULN), but those whose ALT or AST are constantly higher than ULN, they can enroll if ALT or AST remain in 3-fold the ULN.~9. Patients with significant active hematological disease; white blood cell (WBC) count \</=2500/uL or neutrophil count \</=1000 uL.~10. Patients on anti-psychotics or who have psychotic disorder and/or psychotic disorder(s) or unstable recurrent affective disorder(s) with a history of suicidal attempt within 2 years.~11. Patients who operate heavy equipment or drive should not be recruited into the study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women with breast cancer~* Currently taking an aromatase inhibitor (AI)~* Age \> 50 years of age~* Postmenopausal, or two years since last menstrual cycle~* Urogenital/vulvovaginal symptoms such as vaginal dryness and pain with intercourse~* Changes in sexual health quality of life/sexual functioning since starting AI therapy~Exclusion Criteria:~* The use of other treatments for breast cancer such as chemotherapy or radiation within the past 12 months~* A known sensitivity to medications containing testosterone~* The use of exogenous hormone replacement therapy (HRT) in the past three months, including systemic and local estrogen or testosterone therapy

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vaginal Testosterone (Type: EXPERIMENTAL): Testosterone USP micronized powder supplied by Medisca Pharmacy will be compounded by Precision Compounding pharmacy as testosterone 0.3% per 0.5 milliliters (mL) in pharmabase cream. The compounded testosterone vaginal cream will be supplied in pre-filled syringes and each 0.5 mL dose will deliver 300 mcg of testosterone daily. The cream will be applied to the vaginal opening once daily for four weeks (28 days).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Male diagnosed with Fabry disease and between 18 and 65 years of age, inclusive~* Body mass index between 18-35 kg per meter squared~* Had initiated treatment with agalsidase at least 1 month prior to screening, and had received at least 2 infusions before screening~* Had stable dose level, dosing regimen, and form of agalsidase for at least 1 month before screening~* Had an estimated creatinine clearance greater than or equal to 50 milliliters (mL)/minute at screening~* Agreed to use medically accepted methods of contraception during the study and for 30 days after study completion~* Were willing and able to provide written informed consent~Exclusion Criteria:~* Had a documented transient ischemic attack, ischemic stroke, unstable angina, or myocardial infarction within the 3 months before screening~* Had clinically significant unstable cardiac disease (for example, cardiac disease requiring active management, such as symptomatic arrhythmia, unstable angina, or New York Heart Association class III or IV congestive heart failure)~* History of allergy or sensitivity to study drug (including excipients) or other iminosugars (such as miglustat, miglitol)~* Required a concomitant medication prohibited by the protocol: Glyset® (miglitol), or Zavesca® (miglustat)~* Any investigational/experimental drug or device within 30 days of screening, except for use of investigational enzyme replacement therapy for Fabry disease~* Had any intercurrent illness or condition that might have precluded the participant from fulfilling the protocol requirements or suggested to the investigator that the potential participant might have had an unacceptable risk by participating in this study

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Agalsidase Beta (0.5 mg/kg)-Migalastat (150 mg) (Type: EXPERIMENTAL): None
- Agalsidase Beta (1.0 mg/kg)-Migalastat (150 mg) (Type: EXPERIMENTAL): None
- Agalsidase Alfa (0.2 mg/kg)-Migalastat (150 mg) (Type: EXPERIMENTAL): None
- Agalsidase Beta (0.5 mg/kg)-Migalastat (450 mg) (Type: EXPERIMENTAL): None
- Agalsidase Beta (1.0 mg/kg)-Migalastat (450 mg) (Type: EXPERIMENTAL): None
- Agalsidase Alfa (0.2 mg/kg)-Migalastat (450 mg) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Analgesic Benefit of Preoperative vs. Postoperative Etoricoxib in Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I-III~* weight (kilos) over 40 kg~* height (centimeters) over 155 cm~* non-anemic~* indication for primary TKA (total knee arthroplasty)~Exclusion Criteria:~* history of asthma~* peptic ulcer~* severe hepatic or renal dysfunction~* neuropathies~* bleeding disorders~* uncooperative~* drug abuse~* sensibility to etoricoxib~* paracetamol or morphine~* long acting nonsteroidal antiinflammatory drugs (NSAID) in the last 4 days preoperative~* cerebrovascular and peripheric vascular disease~* arterial hypertension (HTA) not adequately controlled~* congestive heart failure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Group ETORICOXIB PREOP (Type: EXPERIMENTAL): Preoperative (1 h) per os (PO) 120 mg Etoricoxib (Arcoxia) and 1 placebo pill PO at the end of surgery.
- Group ETORICOXIB POSTOP (Type: EXPERIMENTAL): Preoperative (1 h) 1 placebo pill PO and 120 mg Etoricoxib PO at the end of surgery (Arcoxia).
- Group PLACEBO (Type: PLACEBO_COMPARATOR): 1 placebo pill PO 1 h preoperative and 1 placebo pill PO postoperative at the end of surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals' EBV (Epstein Barr Virus) Vaccine (268664).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy adolescent/adult subjects between and including 16 and 25 years of age at the time of screening.~  * Written informed consent obtained from the subject prior to enrolment.~ * Seronegative for EBV antibody.~Exclusion Criteria:~* Administration of immunoglobulin and/or any blood products within the three months (90 days) preceding the first dose of study vaccine or planned administration during the study period.~  * Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.~ * Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.~ * Family history of congenital or hereditary immunodeficiency.~ * Major congenital defects or serious chronic illness.~ * History of any neurologic disorders or seizures, with the exception of a single febrile seizure during childhood.~ * Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.~ * History of intravenous drug abuse within the past 2 years.~ * Known or suspected allergy to any vaccine component.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus defined by fasting glucose ≥ 126 mg/dl or HbA1c ≥ 6.5% or on blood glucose lowering medication~* Age of 18 - 75 years~* Male and Female patients (females of child bearing potential must be using adequate contraceptive precautions)~* Females of childbearing potential or within two years of the menopause must have a negative urine pregnancy test at screening visit~* Informed consent (§ 40 Abs. 1 Satz 3 Punkt 3 AMG) has to be given in written form.~Exclusion Criteria:~* Any other form of diabetes mellitus than type 2 diabetes mellitus~* Use of insulin, glitazone, gliptine or SGLT-2 inhibitor within the past 3 months~* Patients with more than one oral blood glucose lowering medication~* Any other oral antidiabetic drug that cannot be discontinued for the study period~* HbA1c ≥ 10%~* Fasting plasma glucose \> 240 mg/dl~* Any history of stroke, transient ischemic attack, instable angina pectoris, or myocardial infarction within the last 6 months prior to study inclusion~* UACR ≥ 300 mg/g (early morning spot urine)~* eGFR \< 60 ml/min/1.73m²~* Uncontrolled arterial hypertension (RR ≥ 180/110 mmHg)~* Congestive heart failure (CHF) NYHA stage III and IV~* Severe disorders of the gastrointestinal tract or other diseases which interfere the pharmacodynamics and pharmakinetics of study drugs~* Significant laboratory abnormalities such as SGOT or SGPT levels more than 3 x above the upper limit of normal range~* Drug or alcohol abusus~* Pregnant or breast-feeding patients~* Use of loop diuretics~* History of repetitive urogenital infection per year~* Body mass index \> 40 kg/m²~* Triglyceride levels \> 1000 mg/dl~* HDL-cholesterol levels \< 25 mg/dl~* Any patient currently receiving chronic (\>30 consecutive days) treatment with an oral corticosteroid~* History of epilepsia or history of seizures~* Patients being treated for severe auto immune disease e.g. lupus~* Participation in another clinical study within 30 days prior to visit 1~* Individuals at risk for poor protocol or medication compliance~* Subject who do not give written consent, that pseudonymous data will be transferred in line with the duty of documentation and the duty of notification according to § 12 and § 13 GCP-V

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Empagliflozin (Type: ACTIVE_COMPARATOR): Empagliflozin, 25 mg/day, oral administration, 6 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, oral administration, 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete